Open AccessAlbumin: Indications in chronic liver disease
Author(s) -
Tufoni Manuel,
Zaccherini Giacomo,
Caraceni Paolo,
Bernardi Mauro
Publication year - 2020
Publication title -
ueg journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.667
H-Index - 35
eISSN - 2050-6414
pISSN - 2050-6406
DOI - 10.1177/2050640620910339
Subject(s) - medicine , spontaneous bacterial peritonitis , hepatorenal syndrome , ascites , cirrhosis , albumin , acute kidney injury , paracentesis , gastroenterology , intensive care medicine , kidney disease
Albumin is currently employed as a plasma expander to prevent and treat specific complications of cirrhosis with ascites, such as the prevention of paracentesis‐induced circulatory dysfunction and renal dysfunction induced by spontaneous bacterial peritonitis, as well as the diagnosis and treatment of acute kidney injury and hepatorenal syndrome. Recently, evidence has shown that long‐term albumin administration in patients with decompensated cirrhosis reduces mortality and incidence of complications, eases the management of ascites, is cost effective, and has a good safety profile.